Sugemalimab
- Product Name
- Sugemalimab
- CAS No.
- 2256084-03-2
- Chemical Name
- Sugemalimab
- Synonyms
- Sugemalimab;Sugemalimab (anti-PD-L1);Research Grade Sugemalimab;Research Grade Sugemalimab (DHJ70110)
- CBNumber
- CB810616945
- Formula Weight
- 0
- MOL File
- Mol file
Sugemalimab Property
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Sugemalimab Chemical Properties,Usage,Production
Uses
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research[1].
in vivo
Sugemalimab (CS1001) signifcantly inhibits tumor growth in the subcutaneous MC38-hPD-L1 murine colon carcinoma (murine MC38 cells expressing human PD-L1) in human PD-1 knock-in mouse model[2].
Sugemalimab not only enhances the cytotoxic T cell/regulatory T cell ratio, but also significantly upregulates M1 macrophage and down-regulated MDSC (myeloid-derived suppressor cells) population in D-1/PD-L1 dual knock-in mice implanted with MC38-hPD-L1 tumor[2].
References
[1] Dhillon S, et al. Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599. DOI:10.1007/s40265-022-01693-4
[2] Zhang J, et al. The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation. Cancer Research, 2020, 80(16_Supplement): 3260-3260.
Sugemalimab Preparation Products And Raw materials
Raw materials
Preparation Products
Sugemalimab Suppliers
- Tel
- +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 19961
- Advantage
- 58